148 related articles for article (PubMed ID: 27004307)
1. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
2. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.
Büyükkurt N; Özcan MA; Ergene Ü; Payzın B; Tunalı S; Demirkan F; Özsan H; Pişkin Ö; Ündar B
Turk J Haematol; 2015 Jun; 32(2):152-7. PubMed ID: 26316483
[TBL] [Abstract][Full Text] [Related]
3. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.
Ahlgrimm M; Pfreundschuh M; Kreuz M; Regitz E; Preuss KD; Bittenbring J
Blood; 2011 Oct; 118(17):4657-62. PubMed ID: 21900198
[TBL] [Abstract][Full Text] [Related]
4. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
[TBL] [Abstract][Full Text] [Related]
5. FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy.
Prochazka V; Papajik T; Gazdova J; Divoka M; Rozmanova S; Faber E; Raida L; Kucerova L; Langova K; Jarosova M; Indrak K
Neoplasma; 2011; 58(3):263-70. PubMed ID: 21395368
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of rituximab therapy on diffuse large B-cell lymphoma with different Fcgamma RIIIA gene polymorphisms: a prospective study].
Zhang W; Wang X; Duan MH; Li J; Zhou DB
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(6):400-2. PubMed ID: 19567119
[TBL] [Abstract][Full Text] [Related]
7. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
9. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
[TBL] [Abstract][Full Text] [Related]
10. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
[TBL] [Abstract][Full Text] [Related]
11. [FcγRIII a polymorphisms and efficacy of Rituximab combined chemotherapy for diffuse large B-cell lymphoma in Chinese patients].
Zhuang Y; Qiao C; Yang G; Shen Y; Qian X; Yang L; Xu W; Li J
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):816-21. PubMed ID: 25246250
[TBL] [Abstract][Full Text] [Related]
12. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
13. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.
Zhang W; Wang X; Li J; Duan MH; Zhou DB
Chin Med J (Engl); 2010 Jan; 123(2):198-202. PubMed ID: 20137370
[TBL] [Abstract][Full Text] [Related]
14. FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV.
Talathi SP; Shaikh NN; Pandey SS; Saxena VA; Mamulwar MS; Thakar MR
BMC Infect Dis; 2019 Dec; 19(1):1053. PubMed ID: 31842762
[TBL] [Abstract][Full Text] [Related]
15. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
17. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.
Keane C; Nourse JP; Crooks P; Nguyen-Van D; Mutsando H; Mollee P; Lea RA; Gandhi MK
Intern Med J; 2012 Oct; 42(10):1113-9. PubMed ID: 21883784
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
[TBL] [Abstract][Full Text] [Related]
19. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]